Kyowa's bet on Kura pays off as partners' oral med for AML subset wins FDA approval

Kyowa Kirin’s big bet on Kura Oncology has paid off in short order, delivering an FDA approval for a medicine to treat a subset of patients with acute myeloid leukemia.